125541-12-0

Basic information

• Product Name: [1,4''-Bipiperidine]-1''-carboxylic acid 1,1-dimethylethylester
• Synonyms: [1,4''-Bipiperidine]-1''-carboxylic acid 1,1-dimethylethylester;[1,4'-Bipiperidine]-1'-carboxylic acid 1,1-dimethylethyl ester;tert-Butyl 1,4'-bipiperidine-1'-carboxylate;[1,4'-Bipiperidine]-1'-carbonyl-1'-carboxylic Acid tert-Butyl Ester
• CAS NO: 125541-12-0
• Molecular Formula: C₁₅H₂₈N₂O₂
• Molecular Weight: 268.398
• Product Categories: Heterocycles
• Mol File: 125541-12-0.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: Dichloromethane, Ethyl Acetate, Methanol
• CAS DataBase Reference: [1,4''-Bipiperidine]-1''-carboxylic acid 1,1-dimethylethylester(CAS DataBase Reference)
• NIST Chemistry Reference: [1,4''-Bipiperidine]-1''-carboxylic acid 1,1-dimethylethylester(125541-12-0)
• EPA Substance Registry System: [1,4''-Bipiperidine]-1''-carboxylic acid 1,1-dimethylethylester(125541-12-0)

Safety Data

• Hazardous Substances Data: 125541-12-0(Hazardous Substances Data)

Usage

Chemical Properties

Light Yellow Oil

Uses

[1,4'-Bipiperidine]-1'-carbonyl-1'-carboxylic Acid tert-Butyl Ester can be used in the preparation of inhibitors for treatment of neurodegenerative diseases.

Upstream product

• 944411-93-2 [1,4']bipiperidinyl-1'-carboxylic acid (4-bromo-phenyl)amide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 4897-50-1 4-piperidinopiperidin 
• 64-18-6 formic acid 
• 1608129-80-1 C₁₉H₂₂ClN₃O₄ 
• 1608129-79-8 C₁₉H₂₂ClN₃O₄ 
• 1608129-78-7 C₁₉H₂₁F₂N₃O₅ 
• 1608129-77-6 C₁₉H₂₃N₃O₅ 
• 1040724-79-5 5-amino-3-(4-methoxyphenyl)pyrazole-1-carboxylic acid tert-butyl ester 
• 110-89-4 piperidine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 4897-50-1 4-piperidinopiperidin 
• 172281-92-4 1,4'-bipiperidine hydrochloride 

Relevant articles and documents

CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF

A compound exerts a strong analgesic effect against pain, in particular, neuropathic pain and/or fibromyalgia syndrome. The cyclic amine derivative is represented by formula, a prodrug thereof or a pharmacologically acceptable salt thereof: wherein A represents a group represented by Formula (IIa), (IIb) or (IIc): wherein R3 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, R4 represents a hydrogen atom or an alkylcarbonyl group having 2 to 6 carbon atoms or an alkyl group having 1 to 6 carbon atoms and optionally substituted with an alkylcarbonylamino group having 2 to 6 carbon atoms and n represents 1 or 2, in which when R3 and R4 each independently represent an alkyl group having 1 to 6 carbon atoms, R1 represents an alkyl group having 1 to 6 carbon atoms and substituted with a hydroxyl group, an amino group or a carboxyl group.

Design and synthesis of a hybrid series of potent and selective agonists of α7 nicotinic acetylcholine receptor

α7 nicotinic acetylcholine receptor agonists are promising therapeutic candidates for the treatment of cognitive impairment. As a follow up of our internal medicinal chemistry program we investigated a novel series of α7 nAChR agonists. Starting from molecular docking studies on two series of molecules recently developed in our laboratories, an alternative scaffold was designed attempting to combine the optimal features of these previously identified urea and pyrazole compounds. Based on our previous SAR knowledge and on predicted drug-like properties, a small library was synthesized in parallel manner, affording compounds with excellent α7 nAChR activity, selectivity and preliminary ADME profile.